Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Expands PerkinElmer Partnership, Pens SNPcode Deal with Exelixis

NEW YORK, Jan 10 - Orchid BioSciences and PerkinElmer said Wednesday that PerkinElmer has obtained a license for use of Orchid's SNP-it single-base primer extension technology for SNP scoring applications on DNA sequencers.

In a separate announcement, Orchid and Exelixis said they have signed a collaboration agreement for Exelixis researchers to evaluate Orchid’s custom SNPcode genotyping assays .

The agreement with PerkinElmer is Orchid's third with the company. Last week, Orchid granted PerkinElmer exclusive rights to develop and market SNP-it-based reagent kits for use with fluorescence polarization laboratory systems. Previously, Orchid purchased a license for exclusive use of PerkinElmer's terminator reagents for SNP scoring.

Under the terms of the agreement, PerkinElmer Life Sciences will produce and sell reagent kits, software, and instruments incorporating Orchid's SNP-it technology for performing SNP analyses on capillary and slab gel DNA sequencers.  

Under the terms of the agreement with Exelixis, Exelixis researchers will evaluate SNPcode genotyping assays for a range of SNP studies conducted at Exelixis.

Further terms of the agreements were not disclosed.

The Exelixis agreement marks the introduction of Orchid’s custom SNPcode kits, assays for customized high-density SNP analyses using Affymetrix GenFlex tag arrays and instrument systems.

Orchid said that Exelixis researchers would be able to customize and analyze over 100 different SNPs simultaneously using SNPcode. According to Orchid, this is greater than a ten-fold increase over current technology and the first commercial product with this capability.

SNPcode is being developed under a December 1999 agreement with Affymetrix, under which Orchid develops, manufactures, supplies and supports SNP-it reagent kits that can be customized by the end user.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.